Sign in

CIK 0001420565

  • Non-accelerated filer
  • Smaller reporting company

Rein Therapeutics, Inc.

Sign in to watch
Ticker
RNTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
134196017
Phone
+1 737-802-1989
Business address
12407 N. MOPAC EXPY., SUITE 250 #390, AUSTIN, TX, 78758
Former names
Aileron Therapeutics, Inc., AILERON THERAPEUTICS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2017-07-05 Kapnick Scott Director Conversion · Series E-2 Preferred Stock −612,002 0
2017-07-05 Kapnick Scott Director Conversion · Series E-3 Preferred Stock −1,266,130 0
2017-07-05 Kapnick Scott Director Conversion · Series F Preferred Stock −487,776 0
2017-07-05 Ambros Reinhard J. Director Conversion +2,277,515 2,277,515
2017-07-05 Ambros Reinhard J. Director Purchase +266,667 $15.00 $4.0M 2,544,182
2017-07-05 Ambros Reinhard J. Director Conversion · Series C Preferred Stock −2,967,025 0
2017-07-05 Ambros Reinhard J. Director Conversion · Series C-2 Preferred Stock −4,238,607 0
2017-07-05 Ambros Reinhard J. Director Conversion · Series D Preferred Stock −6,781,770 0
2017-07-05 Ambros Reinhard J. Director Conversion · Series E-2 Preferred Stock −2,644,558 0
2017-07-05 Ambros Reinhard J. Director Conversion · Series E-3 Preferred Stock −2,293,829 0
2017-07-05 Ambros Reinhard J. Director Conversion · Series F Preferred Stock −3,705,882 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion +2,277,515 2,277,515
2017-07-05 Novartis Bioventures Ltd 10% owner Purchase +266,667 $15.00 $4.0M 2,544,182
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series C Preferred Stock −2,967,025 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series C-2 Preferred Stock −4,238,607 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series D Preferred Stock −6,781,770 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series E-2 Preferred Stock −2,644,558 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series E-3 Preferred Stock −2,293,829 0
2017-07-05 Novartis Bioventures Ltd 10% owner Conversion · Series F Preferred Stock −3,705,882 0
2017-06-28 Dougherty Donald SVP & Chief Financial Officer Grant or award · Stock Option (right to buy) +140,887 140,887

Page 16 of 16 · 320 trades